Omeros (NASDAQ:OMER) Given Neutral Rating at Wedbush

Wedbush reissued their neutral rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Monday, RTT News reports. Wedbush currently has a $18.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also commented on OMER. BidaskClub lowered Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 9th. Cantor Fitzgerald reiterated a buy rating and issued a $71.00 price objective on shares of ExlService in a research report on Monday, May 6th. ValuEngine lowered Yirendai from a sell rating to a strong sell rating in a research report on Wednesday, June 26th. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 28th. Finally, Zacks Investment Research upgraded DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $25.80.

Shares of OMER stock opened at $15.49 on Monday. The stock has a 50-day moving average price of $16.17. The firm has a market capitalization of $756.51 million, a price-to-earnings ratio of -6.98 and a beta of 3.04. Omeros has a 12 month low of $10.30 and a 12 month high of $27.00.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The company had revenue of $21.80 million during the quarter, compared to analysts’ expectations of $23.18 million. The firm’s revenue for the quarter was up 1271.1% on a year-over-year basis. During the same period last year, the firm posted ($0.62) EPS. Sell-side analysts anticipate that Omeros will post -1.68 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in OMER. Advisory Services Network LLC acquired a new position in shares of Omeros during the 1st quarter worth about $69,000. Legal & General Group Plc grew its position in shares of Omeros by 12.7% during the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 945 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Omeros by 16,167.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 9,862 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Omeros by 417.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 12,911 shares during the period. Finally, Miramar Capital LLC acquired a new position in shares of Omeros during the 4th quarter worth about $192,000. Hedge funds and other institutional investors own 52.12% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: CD Ladder

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.